I-SENS, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
August 15, 2022 at 08:13 pm
Share
i-SENS, Inc. reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported sales was KRW 61,764.23 million compared to KRW 58,379.98 million a year ago. Net income was KRW 2,417.24 million compared to KRW 8,862.36 million a year ago. Basic earnings per share from continuing operations was KRW 88 compared to KRW 326 a year ago. Diluted earnings per share from continuing operations was KRW 88 compared to KRW 325.5 a year ago. Basic earnings per share was KRW 88 compared to KRW 326 a year ago.
For the six months, sales was KRW 1,996.29 million compared to KRW 927.51 million a year ago. Net income was KRW 15,417.77 million compared to KRW 15,809.55 million a year ago. Basic earnings per share from continuing operations was KRW 562.5 compared to KRW 581.5 a year ago. Diluted earnings per share from continuing operations was KRW 562 compared to KRW 580.5 a year ago. Basic earnings per share was KRW 562.5 compared to KRW 581.5 a year ago. Diluted earnings per share was KRW 562 compared to KRW 580.5 a year ago.
i-SENS, Inc. is a Korea-based company mainly engaged in the manufacture and sale of biosensors. The Companyâs products consist of blood glucose monitoring systems, including blood glucose monitors, blood glucose meters, glucose monitors, blood glucose meter kits and blood sugar meters under the brand names of CareSens, MedTrust, BGStar, Barozen and others; electrolyte analyzers and cartridges; immunosensors, as well as other related accessories, such as connectors, lancets, blood glucose data management software and lancing devices, among others. The Company distributes its products within domestic market and to overseas markets including Japan, Europe, the United States and others.
I-SENS, INC. 
